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Abstract
Background: The aim of this study is to quantitatively evaluate the effect of rhBMP-2 for repair of bone defects
after cyst enucleation using the osteogenesis index (OI).
Methods: Under general anesthesia, 10 patients (12 lesions) underwent oral or maxillofacial surgery for cyst
enucleation. Postoperatively, 12 lesions were divided into two groups: group A (six lesions) was treated with
absorbable collagen sponge (ACS) in combination with rhBMP-2, and group B (six lesions) was treated with
ACS alone. After 3 months, cone-beam computed tomographic scans were obtained to measure changes in
the volume of the lesions. We then calculated the OI of each group at two different Hounsfield units to
determine any statistically significant difference between these two groups (Mann–Whitney U test).
Results: As tested at the level of new bone, the mean OI was 72.37 % in group A and 55.08 % in group B —a
statistically significant difference (p = 0.041). As tested at the level of mature bone, the mean OI was 27.47 % in
group A and 18.88 % in group B, but the difference was not statistically significant (p = 0.394).
Conclusions: The application of rhBMP-2 after maxillofacial cyst enucleation accelerated new bone formation in
the bone defects. Thus, the use of rhBMP-2 in combination with ACS may be considered an alternative to conventional
bone grafting in some patients with postoperative bone defects.
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Background
Bone defects in the oral and maxillofacial region have
many different causes, such as infection, trauma, le-
sions, or invasive surgery. Because such defects require
faster healing and complete reconstruction to achieve
functional and esthetic recovery, numerous studies and
relentless efforts have been undertaken to fulfill these
requirements. As a result, a variety of bone graft mate-
rials and osteogenic factors have been examined but
have not led to ideal alternatives or substitutes, so rele-
vant studies are ongoing.
Bone morphogenic proteins (BMPs) were discovered
in 1965 by Urist [1], revealing their ability to differenti-
ate undifferentiated osteogenic progenitor cells. Unlike
conventional bone graft materials, which are only
osteoconductive, BMPs are osteoinductive and there-
fore represent an optimal alternative to bone grafting
for reconstruction of the oral and maxillofacial region
[2]. Various applications of rhBMP-2 have been ex-
plored since it was approved in 2007 as a substitute for
autografts in maxillary sinus augmentation and alveolar
ridge defects around an extraction socket. Previous
studies have demonstrated that rhBMP-2 is effective for
cleft lip and palate, alveolar bone augmentation, sinus
augmentation, osteonecrosis of the jaw, and reconstruc-
tion of the oral and maxillofacial region [3–5].
Intrabony cysts are common lesions of the oral and
maxillofacial region and often require surgical removal.
In many cases, after removal of the cyst, bone grafting is
performed using a particle-type bone graft material. Re-
cently, however, because bone graft materials may be-
come dispersed or may migrate depending on the size or
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location of the defect and the bony housing of the lesion
[6], absorbable collagen sponge (ACS) with absorbed
BMPs has occasionally been used instead [7].
Although many studies have already shown the bone
regenerative effects of rhBMP-2, most of these were in
vitro or animal studies in which rhBMP-2 was added to
other bone graft materials, and some of the clinical re-
ports involved non-quantitative methods. Our study
was intended to analyze the bone regenerative effects
of rhBMP-2 quantitatively based on cone-beam com-
puted tomographic (CBCT) images of patients treated
with and without rhBMP-2.
Methods
Patients
We evaluated 38 patients who visited the Department of
Oral and Maxillofacial Surgery at Ajou University Hospital
in South Korea from January 1, 2014, through March 31,
2015, and who underwent cyst enucleation under general
anesthesia. For our study, the following selection criteria
were applied:
Inclusion criteria
 Both preoperative and 3-month postoperative
CBCT images were available.
 ACS alone or rhBMP-2 plus ACS was used for
bone defect repair.
Exclusion criteria
 Recipients of bone grafts (allogenic or xenogenic
bone material).
 Patients with diseases related to bone metabolism
(e.g., osteoporosis).
Based on these criteria, we selected 10 patients for
study, two of whom each had one additional, independ-
ent lesion, for a total of 12 lesions. Human CBCT data
were used in this study but patient consent was not
necessary. This study was reviewed and approved by the




Two operators performed cyst enucleation for 12 lesions.
After a retrospective chart review, we divided the 12
cases into two groups of six lesions each: group A was
treated with rhBMP-2 plus ACS, and group B was
treated with ACS alone. Preoperative and 3-month post-
operative lesion volumes were measured on CBCT im-
ages, and the osteogenesis index was calculated in each
case, after which, a statistical analysis was performed.
Surgical procedure
After cyst enucleation under general anesthesia, ACS
with absorbed rhBMP-2 was applied on the bone de-
fects in group A and primary closure was completed. In
group B, ACS alone was applied after cyst enucleation,
with subsequent primary closure (Fig. 1). Up to five
units of ACS was used and up to 1.0 mg of rhBMP-2
(1 mg/mL) was used, depending on the size of the le-
sion. The rhBMP-2 used in this study was NOVOSIS
(Daewoong Pharmaceutical Company, Seoul, South Korea),
and the ACS was either Ateloplug (Bioland, Cheonan,
South Korea) or Rapiderm Plug (Dalim Tissen, Seoul,
South Korea).
Lesion volume measurements
Each case was analyzed using Simplant software (Materi-
alise Dental, Leuven, Belgium). From among the user’s
tools, we selected only those pixels (Fig. 2) within the
preset range of Hounsfield units (minimum = −1024 HU;
maximum = 200 or 600 HU) for all the coronal or axial
images believed to include lesions. The selected pixels
were then remodeled into three-dimensional images,
and the volumes were calculated. Hounsfield units
ranged from −1024 (minimum) to 200 (new bone level)
Fig. 1 Surgical procedures for group A and group B. In group A, ACS with absorbed rhBMP-2 was applied to the bone defects. In group B, ACS
alone was applied to the bone defects
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or 600 (mature bone level) (maximum), in reference to
the studies performed by Norton and Gamble [8], Sha-
purian et al. [9], and Tajima et al. [10] (Fig. 3). Specific-
ally, we defined two ranges: range 1 included −1024 <
HU < 200 and range 2 included −1024 < HU < 600. For
range 1, pixels with volumes of < 200 HU were regarded
as a lesion; for range 2, pixels with volumes of < 600 HU
were regarded as a lesion.
To minimize any possible visual errors during meas-
urement, the patient’s head position on CBCT images
was repositioned prior to volume measurement by using
the line connecting the bilateral orbitales on the coronal
plane, the line connecting the anterior nasal spine
(ANS) and the cervical vertebra on the horizontal plane,
and the line connecting the ANS to the posterior nasal
spine (PNS) on the sagittal plane. To ensure accuracy,
volume measurements were done twice in each case,
and the mean results were used in this study.
Calculation of OI
Preoperative lesion volume was defined as V0 and post-
operative lesion volume as Vh (HU = 200 or 600) (Fig. 4).
The OI was calculated as (V0 −Vh)/V0 (%).
Assessment and statistical analysis
Using OI, we compared osteogenesis in groups A and B,
and differences with a p value of < 0.05 were considered
statistically significant. The Mann–Whitney U test and
SPSS version 22.0 (IBM, NY, USA) were employed as the
statistical technique and software program, respectively.
Results
The patients ranged in age from 16 to 50 years (mean
age = 36.25), and the ratio of male-to-female patients
was 9:1. Of the 12 lesions, nine were located in the man-
dible and the other three in the maxilla. Histological
findings for the individual lesions indicated that there
were nine dentigerous cysts, two periapical cysts, and
one keratocystic odontogenic tumor (KCOT) (Table 1).
All the lesions healed with no remarkable complications.
The measurements of preoperative lesion volume (V0)
ranged from 1.24 to 14.82 cm3, with a mean of 5.25 cm3.
The OI measurements at the level of new bone ranged
from 29.88 to 88.21 %, with a mean of 63.72 %, and at
the level of mature bone from 5.12 to 55.33 %, with a
mean of 23.17 %. When postoperative lesion volume was
measured, increases in the number of Hounsfield units
BA C
Fig. 2 Selection of pixels within the range of Hounsfield units desired (selection process). a Original CBCT image. b Drawing of lesional area.
c Selected pixels
New bone level Mature bone level
Fig. 3 Remodeling to a three-dimensional model. Selection of pixels regarded as lesions at the new bone level and the mature bone level for all
computed tomographic images
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were seen throughout the lesions, especially around the
margins.
When tested at the new bone level, the mean OI was
72.37 % for group A and 55.08 % for group B—a statisti-
cally significant difference (p = 0.041). However, when
tested at the mature bone level, the mean OI was 27.47 %
for group A and 18.88 % for group B, a difference that did
not reach statistical significance (p = 0.394) (Table 2 and
Fig. 5).
Discussion
Human bone regenerates through patterns of maturation
similar to those of bone growth in response to bone de-
fects of any cause. Stable bone healing is achieved when
there is an adequate blood supply and immobilization at
the site of the defect. For the first 4 weeks, angiogenic
and osteogenic cells originate from the surrounding
bone walls and periosteum, while woven bone forms
around the defect. These processes are governed by vari-
ous cytokines and growth factors [11–15].
Ettl et al. suggested that although primary closure after
cyst enucleation can be accomplished without bone
grafts, further research regarding growth factors, osteo-
blasts, stem cells, and other components is needed to
understand this process more fully [16]. Bone defects up
to 3 cm in diameter usually undergo complete ossifica-
tion after 12 months, while larger bone defects may re-
quire a longer period of ossification (24 months or
more) [17, 18]. In spite of the obvious need for add-
itional treatment to accelerate healing (e.g., bone graft-
ing), such measures cannot always be taken when
possible complications such as infection or migration
are of concern. Recently, ACS with absorbed rhBMP-2
has been applied in such situations.
In his primate study, Boyne reported that rhBMP-2
alone was useful even without bone graft material for
the reconstruction of facial bone defects after mandibu-
lar hemisection, implant, and cleft repair [19]. After
reviewing the literature on alveolar ridge augmentation,
maxillary sinus augmentation, and/or extraction socket
preservation, Freitas et al. reported that ACS with
absorbed rhBMP-2 appeared to function as an alterna-
tive to autografting in alveolar ridge or maxillary sinus
augmentation [20]. Balaji reported the use of rib graft-
ing and rhBMP-2 following removal of an aneurysmal
bone cyst [2], and in 2014, Lee et al. also reported the
use of rhBMP-2 and β-TCP/HA (tricalcium phosphate/
hydroxyapatite) in five patients with cysts [21].
Unfortunately, however, there have been some limi-
tations to the use of rhBMP-2 despite the successful
outcomes described above. These include the shorter
half-life of BMP-2 and its rapid elimination at the ap-
plication site, which requires a high dose of BMP-2
and thus expensive medical costs, overgrowth of bone,
and unwanted side effects, including swelling due to im-
mune reactions [7, 22, 23]. According to a recent report,
excessively high doses of BMP-2 may cause oral squamous
cell carcinoma [24]. However, we did not observe compli-
cations in any of the patients treated at our hospital.
One can compensate for the abovementioned disad-
vantages of BMP by selecting an appropriate carrier.
Currently available carriers include HA, TCP, DBM,
Mature bone levelNew bone level
BA C
Fig. 4 Initial lesion and reduced lesion after 3 months. a Preoperative lesion. b Postoperative lesion at new bone level. c Postoperative lesion at
mature bone level
Table 1 Characteristics of the 12 lesions




16 M Mandible DC 14.82
50 F Mandible DC 1.98
21 M Mandible KCOT 6.47
45 M Mandible DC 2.27
41 M Mandible DC 3.14
20 M Mandible DC 5.02
B
(ACS alone)
51 M Mandible DC 2.30
48 M Maxilla PC 6.64
37 M Mandible DC 1.24
37 M Mandible DC 2.67
45 M Maxilla DC 2.95
40 M Mandible PC 13.48
DC dentigerous cyst; PC periapical cyst; KCOT keratocystic odontogenic tumor
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hydrogel, and ACS. Referring to the existing literature,
Geiger et al. described “enhancement of osteogenic ac-
tivity of BMP with a restrictive release of BMP at an
effective dose during a period coincident with the ac-
cumulation and proliferation of target cells” [25]. Li
and Wozney reported that the releasing periods of
rhBMP-2 were at least twice as long when treatment
included the ACS compared with the control treat-
ment without the sponge, and ACS is an appropriate
carrier for BMP application [26]. In contrast, in 2008,
Carter et al. mentioned that although ACS is of value
for the delivery of BMP and offers good space-
maintaining ability, it should be used with caution
because its overcompressed use may interfere with
normal bone formation [7].
Bone density can be assessed by measuring Hounsfield
units and has different values depending on the type of
bone. Very dense cortical bone is expressed as 600 HU
or more, the dense cortical/spongy bone as 400 through
600 HU, and low-density bone as 200 HU or less [8, 9].
In 2013, Tajima et al. reported that the density of peri-
implant, new bonelike tissue ranged from 185 to
713 HU (mean ± SD = 323 ± 156.2) [10].
Huh et al. found that combination therapy with bovine
bone (Bio-Oss) and rhBMP-2 leads to more new bone
generation than does bovine bone monotherapy and that
rhBMP-2 enhanced bone regeneration [27]. In our study,
the mean OI was higher in the rhBMP-2 treatment
group A than in the group B, and the difference was sta-
tistically significant for new bone levels with maximum
number of Hounsfield units set at 200. This result sug-
gests that rhBMP-2 contributes significantly to new bone
generation in the human body as well.
This study had the following limitations: difficulty in
determining the margin when measuring postoperative
lesion volume owing to the need for intraoperative oste-
otomy to approach the lesion; several diagnoses of the
lesions; preoperative secondary infections due to the le-
sions; the degree of defect in the bony housing; and no
consideration of the number of absorbable collagen
sponges or the quantity of rhBMP-2 actually applied
during the operation. Nevertheless, this study is mean-
ingful in that we used a quantitative method to analyze
the effect of rhBMP-2 in human subjects. Further stud-
ies will be needed to perform histomorphometric ana-
lyses of the effects of rhBMP-2 in the human body.
Conclusions
When rhBMP-2 was used to repair bone defects that re-
main after cyst enucleation, new bone formation was in-
creased. Thus, the combination of rhBMP-2 and ACS
could be considered as an alternative to conventional
bone grafts. We believe that rhBMP-2 is worthy of being
applied to bone defects in the oral and maxillofacial re-
gion in certain cases.
Ethics approval and consent
Human CBCT data were used in this study, but consent
for patients was not necessary. This study was reviewed
Table 2 Preoperative and 3-month postoperative mean volume (±SD) and mean OI (±SD) of lesion
Group V0 New bone Mature bone
V200 (cm




5.62 ± 4.82 1.67 ± 1.60 72.37 ± 14.39 4.56 ± 4.57 27.47 ± 17.09
B
(ACS alone)
4.88 ± 4.60 1.79 ± 1.14 55.08 ± 15.26 3.81 ± 3.21 18.88 ± 11.15
V0 preoperative volume; V200 volume at new bone level (< 200 HU); V600 volume at mature bone level (< 600 HU); OI osteogenesis index
Fig. 5 OI values for group A and group B. The OI of groups A and B at the level of new bone (left) and the level of mature bone (right). At the
new bone level, a statistically significant difference was seen between group a and group b (p < 0.05)
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and approved by the Institutional Review Board of Ajou
University Hospital (AJIRB-MED-MDB-15-203).
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The dataset supporting the conclusions of this article is
included in Additional file 1.
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